Companies in #Autoimmune Diseases

Adicet Bio is a clinical-stage biotechnology company based in Redwood City, California, discovering and developing off-the-shelf allogeneic gamma delta T cell therapies engineered with chimeric antigen receptors for autoimmune diseases and cancer, alongside a preclinical in vivo CAR-T platform. Its lead candidate, prula-cel (formerly ADI-001), is an anti-CD20 CAR gamma delta T cell therapy being developed in systemic lupus erythematosus with or without lupus nephritis; on September 28, 2026 the company reported updated Phase 1 data from 22 efficacy-evaluable patients showing 54% DORIS remission at 12 months and complete renal response in 50% of evaluable lupus nephritis patients after a single dose off immunosuppression, with no cases of IEC-HS and no ICANS, and said it expects to begin a pivotal study in the fourth quarter of 2026. Its second program, ADI-212, is an anti-CD70 CAR gamma delta T cell therapy with an FDA-cleared IND in metastatic castration-resistant prostate cancer and a Phase 1 study expected to initiate in the fourth quarter of 2026.

Clinical-stage biotech developing allogeneic umbilical cord blood-derived T-regulatory cell therapies for autoimmune diseases and inflammatory disorders.

Clinical-stage biopharmaceutical company developing Immuno-STAT biologics designed to selectively engage disease-relevant T cells for cancer and autoimmune disease; its CUE-221 candidate for chronic spontaneous urticaria hit its Phase 2 primary endpoint in September 2026.

Cullinan Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases and cancer. Its clinical-stage portfolio includes CLN-978, a wholly owned CD19xCD3 bispecific T cell engager being studied as an off-the-shelf subcutaneous therapy for rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease, and zipalertinib, a brain-penetrant EGFR exon 20 insertion inhibitor developed in partnership with Taiho Oncology for non-small cell lung cancer that reported positive Phase 3 REZILIENT3 results in September 2026. The company was founded in 2016, listed on Nasdaq in January 2021, and is led by President and Chief Executive Officer Nadim Ahmed.

Earendil Labs is an AI-powered biotechnology company that combines machine learning, generative protein engineering and high-throughput experimentation to design next-generation biologics for autoimmune and inflammatory diseases and cancer. It works alongside its affiliate Helixon Therapeutics and has collaborations with Sanofi and Genentech.

Immunovant is a clinical-stage immunology company and a trailblazer in anti-FcRn technology, developing targeted therapies that reduce harmful immunoglobulin G autoantibodies to enable normal lives for people with autoimmune diseases. Its lead investigational product, imeroprubart (IMVT-1402), is a fully human monoclonal antibody advancing across multiple autoimmune indications.

Nektar Therapeutics is a clinical-stage immunology company developing immunomodulatory medicines that target regulatory T cells and other immune pathways. Its lead candidate, rezpegaldesleukin (REZPEG), is in Phase 3 development for moderate-to-severe atopic dermatitis.

North Immunology is a privately held biotechnology company developing bispecific antibodies that target orthogonal inflammatory pathways in immune and inflammatory diseases. Its lead program, NOR-101, is a half-life-extended IL-13 x IL-18 bispecific antibody in development for atopic dermatitis. The company is going public through a reverse merger with Aethlon Medical.

Biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Its lead asset LISRAYA (brepocitinib) received FDA approval for dermatomyositis, with Orsini Specialty Pharmacy serving as the specialty pharmacy partner.

A biopharmaceutical company focused on discovering and developing peptide-based novel therapeutics for hematology and hematology-related conditions.

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA splicing modulators using its proprietary SkySTAR platform, with programs in neurology, oncology, autoimmune, and fibrotic diseases.

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases and rare conditions, with a focus on FcRn inhibitors and thyroid eye disease.